Vical To Present Phase 1 Data For Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines
Vical Incorporated (Nasdaq: VICL) announced the scheduled presentation of preliminary human safety and immunogenicity data from a Phase 1 trial of the company’s Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines on Thursday, July 17, at the IBC Life Sciences Next Generation Vaccines conference (National Harbor, MD - July 17-18). Vical’s Vice President of Vaccine Research, Larry R. Smith, Ph.D.
